Trials / Completed
CompletedNCT01912196
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
A Double-Blind, Placebo-Controlled, Randomized Add-On Study of MSI-195 (Methylation Sciences Inc. S-Adenosyl-L-Methionine, SAMe) For Patients With Major Depressive Disorder(MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 376 (actual)
- Sponsor
- MSI Methylation Sciences, Inc. · Industry
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy and safety of 800 mg MSI-195 in reducing symptoms of depression in Major Depressive Disorder (MDD)patients with inadequate response to current antidepressant therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MSI-195 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2013-07-31
- Last updated
- 2016-03-18
Locations
35 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01912196. Inclusion in this directory is not an endorsement.